Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population

Cai Mei Zheng, Jia Yi Wang, Tzu Ting Chen, Yun Chun Wu, Yi Lien Wu, Hsin Ting Lin, Sheng Po Chiu, Tian Jong Chang, Jing Quan Zheng, Nain Feng Chu, Yu Me Lin, Sui Lung Su, Kuo Cheng Lu, Jin Shuen Chen, Fung Chang Sung, Chien Te Lee, Yu Yang, Shang Jyh Hwang, Ming Cheng Wang, Yung Ho HsuHung Yi Chiou, Senyeong Kao, Mei Yi Wu, Yuh Feng Lin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It remains unclear how different uses of angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) influence the progression of chronic kidney disease (CKD). This study explored CKD progression in a multicentre, longitudinal cohort study that included 2639 patients with CKD stage 1–5 and hypertension. Patients treated with ACEI or ARB for ≥90 days during a 6-mo period comprised the study group, or no treatment, comprised the control group. The study group was subdivided on the basis of treatment: ACEI monotherapy or ARB monotherapy. Progression of renal deterioration was defined by an average eGFR decline of more than 5 mL/min/1.73 m2/yr or the commencement of dialysis. With at least 1-year follow up, a progression of renal deterioration was demonstrated in 29.70% of the control group and 25.09% of the study group. Patients in the study group had significantly reduced progression of CKD with adjusted odds ratio 0.79 (95% confidence interval: 0.63–0.99). However, when ACEI monotherapy and ARB monotherapy were analyzed separately, none of their associations with CKD progression was statistically significant. In conclusion, ACEI or ARB monotherapy may retard the deterioration of renal function among patients with CKD and hypertension.

Original languageEnglish
Article number2694
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • General

Cite this

Zheng, C. M., Wang, J. Y., Chen, T. T., Wu, Y. C., Wu, Y. L., Lin, H. T., Chiu, S. P., Chang, T. J., Zheng, J. Q., Chu, N. F., Lin, Y. M., Su, S. L., Lu, K. C., Chen, J. S., Sung, F. C., Lee, C. T., Yang, Y., Hwang, S. J., Wang, M. C., ... Lin, Y. F. (2019). Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. Scientific reports, 9(1), [2694]. https://doi.org/10.1038/s41598-019-38991-z